x

Guide to applicants

Innopharma can help you to achieve your goal if your research has potential therapeutic applications or is likely to lead to new treatments and / or diagnostics.

Phase I. Submission of expression of interest.

Research groups interested in participating in this call may contact Innopharma covering the Expression of Interest form on the website. The first call for EoI will be open from 1st till October 31st , 2013, although the call will be continuously open for proposals.

The Expressions of Interest will be peer-reviewed by an expert committee (created ad hoc) using the following criteria:

  • Level of innovation (measured, among other factors, by its ability to generate intellectual property).
  • Potential of transfer to markets or industrial partners.
  • Degree of progress of the project in the value chain (transfer distance to market)

The status and process conditions of each Expression of Interest submitted will be communicated to the principal investigator.

All information will be treated by Innopharma based on this agreement.   legal framework

Phase II. Submission of full proposal

After selecting of Expressions of Interest, projects will be studied in detail from different points of view (innovation, competitive situation, intellectual property, transfer potential, resources, etc..). At this time, a detailed plan containing all the project information will be developed. The elaboration of this document will be a collaborative process between Innopharma and applicant research group, with the advise of experts if necessary.

Subsequently, the complete project will be subject to external evaluation by a board of scientific advisors, experts in business development and intellectual property.

Phase III. Start of projects.

The starting date of the projects is in January 15th, 2014, once the final round of evaluation and selection ends.

What type of projects is Innopharma seeking?

Innopharma seeks projects for discovery and / or development of new therapeutics in collaboration with academic research groups, public research organizations and non-profit foundations.

The candidate projects must rely on Innopharma platform for their valorisation and fit into a shared intellectual property model.

What type of research projects are supported?

Projects must be related to early drug discovery. Examples of the type of research that could be eligible for Innopharma:

  • Target identification and validation.
  • Test small molecules to predict their effectiveness and their potential therapeutic use.
  • Design and synthesis of small molecules with affinity for certain targets.
  • Development of miniaturized assays for HTS.
  • Design of screening cascades to preclinical candidate.
x

Expression of interest form

Your name (required)

Your e-mail (required)

1. Download the expression of interest form on the link that appears on this page and save it to your computer before you start to fill. Some browsers do not allow to write on the form if it has not been stored in the computer. The forms are PDF files and can be completed with Adobe Reader. Adobe Reader is free and available at www.adobe.com.

2. Once covered, the form must be attached from its location on your computer using the "Select file" button.

3. To complete the submission, click on "SEND" button. You will receive a confirmation email when your form has been received.

Download, fill and attach the expression of interest form.

The first call for expression of interest will be open from 1st till October 31st, 2013

x

Frequently Asked Questions (F.A.Q)

1. Who can participate?

Academic research groups, public research organizations and non-profit foundations with the possibility of sharing intellectual property and relying on the Innopharma platform for its valorisation.

2. What kind of projects can apply to this call?
  • Screening of candidate drugs, identification and validation of new therapeutic targets.
  • Small molecules assays to predict their efficacy and potential therapeutic indications.
  • Design and synthesis of small molecules with affinity for targets of interest.
  • Development of miniaturized assays for HTS.
  • Design of screening cascades to preclinical candidates.
3. How is the application process?

Applicants must submit the Expression of Interest form through Innopharma website to provide a preliminary overview of the project.

4. When is the deadline to submit a Expression of Interest form?

First call for EOIs from public institutions or research groups will be open between October 1st and 31st, although the submitting period will be continuously open for proposals.

5. How will the evaluation and selection of the projects be carried on?

Evaluation and selection criteria are based on:

    • Level of innovation (measured, for instance, as the capacity for generating intellectual property).
    • Potential for transference to markets or industrial partners
    • Degree of progress of the project in the chain of value.

Project proposals will be evaluated by a Scientific Committee designated by Innopharma, which includes external advisors, as well as experts in business plans and intellectual property development.

6. When will be evaluated the Expresión of Interest Forms?

Evaluation of pre-proposal will be done between October 15th and November 10th 2013.

7. How can I know the status of a submitted project?

The status and process conditions of each Expression of Interest submitted will be communicated to the principal investigator.

8. If a project is selected, what is the next step?

If a project is selected, the next step will be presenting a full-proposal that details all the contents of the project. The elaboration of this document will be done until first week of December 2013, in a collaborative process between Innopharma and applicant research group, with the help of experts whenever necessary. Therefore, a new evaluation and selection process by an external Scientific Advisory Board (SAB) will determine the selected projects.

9. When should I expect to hear the outcome of this first call?

Selected projects will be known by the second week of January 2014.